| Item | Mean | SD |
|---|---|---|
| Overarching principles | 7.23 | 3.04 |
| Item-1 (starting DMARDs early) | 8.62 | 2.60 |
| Item-2 (remission-monitoring) | 9.49 | 1.44 |
| Item-3 (Methotrexate) | 9.05 | 2.05 |
| Item-4 (DMARDs other than MTX) | 7.99 | 2.21 |
| Item-5 (Monotherapy rather than combination) | 6.28 | 3.09 |
| Item-6 (Adding GCs) | 8.86 | 2.10 |
| Item-7 (Biologics when poor prognosis) | 8.55 | 2.02 |
| Item-8 (responding insufficiently, start TNF inhibitors) | 8.67 | 1.98 |
| Item-9 (Failure in first TNF inhibitor, start another TNF inhibitor or other biologics) | 8.22 | 2.25 |
| Item-10 (Refractory severe RA or biologics contraindicated other synthetic DMARDs ) | 7.87 | 2.24 |
| Item-11 (Intensive medication strategies) | 8.80 | 1.87 |
| Item-12 (Persistent remission tapering of biologics) | 8.15 | 2.29 |
| Item-13 (Sustained long-term remission, cautious titration of synthetic DMARD) | 8.73 | 1.86 |
| Item-14 (Poor prognostic factors combination of MTX with a biologic) | 7.68 | 2.76 |
| Item-15 (progression of structural damage, comorbidities and safety concerns) | 9.41 | 1.42 |
| Self-declared application of overall recommendations, % | 72.42 | 20.53 |